Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1792938

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1792938

Human Immunoglobulin

PUBLISHED:
PAGES: 279 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Human Immunoglobulin Market to Reach US$28.3 Billion by 2030

The global market for Human Immunoglobulin estimated at US$17.0 Billion in the year 2024, is expected to reach US$28.3 Billion by 2030, growing at a CAGR of 8.9% over the analysis period 2024-2030. Autoimmune Disorders Application, one of the segments analyzed in the report, is expected to record a 10.7% CAGR and reach US$12.6 Billion by the end of the analysis period. Growth in the Hematology Diseases Application segment is estimated at 6.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.6 Billion While China is Forecast to Grow at 14.1% CAGR

The Human Immunoglobulin market in the U.S. is estimated at US$4.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.3 Billion by the year 2030 trailing a CAGR of 14.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Global Human Immunoglobulin Market - Key Trends & Drivers Summarized

How Is the Expanding Scope of Immune-Related Disorders Shaping the Use of Human Immunoglobulin?

Human immunoglobulin, a vital blood-derived product rich in antibodies, is increasingly being deployed across a wide range of therapeutic areas, particularly in the management of immune deficiencies and autoimmune disorders. As the global burden of immune-related diseases grows, medical professionals are turning to immunoglobulin therapy for both replacement and immunomodulatory purposes. Primary immunodeficiency disorders, where patients lack the natural ability to produce sufficient antibodies, are among the most common indications for these therapies. In such cases, immunoglobulin infusions are crucial for preventing life-threatening infections and ensuring long-term health stability. The product is also used extensively to treat autoimmune neurological diseases such as chronic inflammatory demyelinating polyneuropathy and myasthenia gravis, where it helps to regulate an overactive immune response. Furthermore, secondary immunodeficiencies caused by chemotherapy, HIV, or bone marrow transplantation are also being managed with human immunoglobulin therapy, highlighting its versatility. The growing awareness among healthcare providers and patients regarding these applications has resulted in a steady increase in demand across hospitals, specialty clinics, and home care settings. As disease awareness rises and diagnostic capabilities improve, more individuals are being correctly identified as candidates for this treatment, further reinforcing the clinical reliance on human immunoglobulin. This expanding therapeutic scope is not only elevating the medical significance of immunoglobulin but is also laying the groundwork for sustained market growth.

Why Are Technological Advancements in Plasma Collection and Purification Enhancing Supply and Safety?

Technological innovation in plasma collection and immunoglobulin purification is playing a transformative role in shaping the reliability, safety, and availability of these vital therapies. The production of human immunoglobulin begins with the collection of plasma from healthy donors, and the introduction of automated apheresis machines has improved both the efficiency and yield of this process. These machines allow for selective extraction of plasma components, reducing donor fatigue while increasing output. Once collected, the plasma undergoes rigorous purification involving processes such as ethanol fractionation, chromatography, and viral inactivation to ensure the removal of pathogens and impurities. These steps are continually being refined to enhance safety without compromising the efficacy of the final product. New filtration methods are allowing manufacturers to achieve higher levels of purity, reducing the risk of adverse reactions in recipients. Moreover, innovations in cold-chain logistics and packaging are improving the stability and shelf life of immunoglobulin preparations, especially important in regions with limited access to refrigerated transport. Many producers are also investing in recombinant technologies and alternative expression systems, though human plasma remains the primary source. These advancements collectively ensure that the supply chain for immunoglobulin is becoming more robust, scalable, and responsive to global demand fluctuations. As more countries seek to establish or expand their plasma collection networks, these technologies provide the blueprint for safer and more efficient immunoglobulin therapies worldwide.

How Are Healthcare Infrastructure and Policy Initiatives Supporting Broader Access to Immunoglobulin Therapy?

Access to human immunoglobulin therapy is being increasingly supported by national healthcare initiatives, international collaborations, and evolving reimbursement structures. In high-income countries, immunoglobulin is generally included in public or private insurance plans, allowing widespread clinical use in hospitals and outpatient care facilities. In recent years, governments in middle-income countries have also begun integrating immunoglobulin into essential medicines lists, recognizing its value in treating immune-related conditions that often go underdiagnosed. Some nations are implementing plasma self-sufficiency programs to reduce reliance on imported products and improve availability through domestic production. Public-private partnerships and nonprofit organizations are facilitating infrastructure development, especially in regions where plasma collection and processing capacity have been historically limited. Additionally, disease-specific advocacy groups have played a crucial role in pushing for equitable access and policy reforms that prioritize timely diagnosis and long-term treatment. Standardized treatment guidelines and updated protocols from international health bodies are also helping physicians around the world understand when and how to use immunoglobulin effectively. Improvements in training and education for healthcare professionals, combined with greater access to diagnostic tools, are ensuring that patients receive appropriate therapy based on evidence-based indications. These systemic efforts are breaking down traditional barriers to immunoglobulin therapy, expanding its reach beyond tertiary hospitals to smaller clinics and rural health centers. As healthcare systems continue to mature and become more inclusive, the infrastructure supporting immunoglobulin use is becoming more reliable, equitable, and aligned with global standards of care.

What Key Factors Are Driving the Global Expansion of the Human Immunoglobulin Market?

The global expansion of the human immunoglobulin market is driven by a confluence of medical, technological, demographic, and strategic factors that reflect growing demand and evolving healthcare priorities. One of the primary drivers is the increasing prevalence of immune deficiencies, both congenital and acquired, coupled with rising diagnostic rates due to improved medical awareness and screening capabilities. An aging global population is also contributing to market growth, as elderly individuals are more susceptible to infections and autoimmune conditions, making them key beneficiaries of immunoglobulin therapy. The rapid advancement of plasma collection and fractionation technology ensures a more stable supply chain, which is essential given the high resource intensity of immunoglobulin production. In parallel, regulatory frameworks are becoming more supportive, with expedited approvals and standardized safety requirements making it easier for new products to enter the market. Pharmaceutical companies are also focusing on the development of subcutaneous formulations and other patient-friendly delivery systems that support home-based care and improve treatment adherence. Strategic investments and mergers in the biopharmaceutical sector are enabling broader distribution networks and deeper market penetration, especially in emerging economies. Additionally, the growing focus on rare diseases and orphan drug incentives is encouraging innovation in niche immunoglobulin therapies for less common indications. As awareness campaigns, clinical training, and government support continue to expand, the human immunoglobulin market is positioned for sustained global growth, offering critical solutions for patients whose immune systems require reliable, effective support.

SCOPE OF STUDY:

The report analyzes the Human Immunoglobulin market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application, Other Applications); End-Use (Hospitals End-Use, Clinics End-Use, Ambulatory Surgery Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • ADMA Biologics, Inc.
  • Baxter International Inc.
  • Bharat Serums and Vaccines Ltd
  • Biotest AG
  • Bio Products Laboratory Ltd (BPL)
  • CSL Behring
  • China National Pharmaceutical Group (Sinopharm)
  • GC Pharma
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Intas Pharmaceuticals Ltd.
  • Kedrion Biopharma
  • LFB S.A.
  • Octapharma AG
  • Reliance Life Sciences
  • Sanquin
  • Shanghai RAAS Blood Products Co.
  • Shire (Now part of Takeda)
  • Sichuan Yuanda Shuyang Pharmaceutical Co.
  • Takeda Pharmaceutical Company Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37131

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Human Immunoglobulin - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Primary Immunodeficiency Disorders Throws the Spotlight on Human Immunoglobulin as a Lifesaving Therapy
    • Growing Use in Autoimmune and Neurological Disorders Propels Demand for Intravenous and Subcutaneous Immunoglobulin
    • Here's the Story: Expanding Indications Beyond PID Strengthens the Business Case for Broader Immunoglobulin Utilization
    • Advancements in Plasma Fractionation Technologies Drive Supply Chain Efficiency and Product Innovation
    • Increasing Awareness and Diagnosis Rates Accelerate Demand Across Both Developed and Emerging Healthcare Markets
    • Here's How Aging Populations Fuel the Need for Immunoglobulin in Chronic Immune-Mediated Conditions
    • Plasma Collection Shortages and Donor Dependency Pose Long-Term Supply Challenges for the Immunoglobulin Market
    • Emergence of Subcutaneous Formulations Sustains Growth by Enabling Home-Based, Self-Administered Treatments
    • Global Expansion of Plasma Collection Centers Expands Addressable Supply and Geographic Market Reach
    • Improved Product Purity and Safety Profiles Drive Adoption Among Pediatric and Geriatric Patient Populations
    • Here's How Biotech Innovation Advances Recombinant Alternatives to Conventional Human-Derived Immunoglobulin
    • Rising Demand in Critical Care and Infectious Disease Management Opens New Emergency Use Scenarios
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Human Immunoglobulin Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Human Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Autoimmune Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hematology Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hematology Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Hematology Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Inflammatory Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Inflammatory Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Inflammatory Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Human Immunoglobulin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Human Immunoglobulin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Human Immunoglobulin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Human Immunoglobulin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!